InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,169.84
(
-0.03%
)
Post# of 252199
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

bellweather1

Send PM Follow Ignore
Followers 11
Posts 2370
Boards Moderated 0
Alias Born 06/08/2010

bellweather1

Re: None

Monday, 02/10/2014 4:03:20 PM

Monday, February 10, 2014 4:03:20 PM

Post# of 252199
TGTX/at BIO CEO Investor Conference

Another "flawless" presentation by Micheal Weiss(lol)...

Seriously, continued absence of any serious toxicities(no MTD)with continued dose escalation into therapeutic ranges of his PIK3delta(TGR-1202)-

emphasized advantages of pricing and therapeutic flexibility with "potential" best in class Anti-CD20 and PI3Kdelta both in house.

Bottom line:continuation of stated plans for pivotal combo trials in 2H 2014...

Worth a listen:

http://www.veracast.com/webcasts/bio/ceoinvestor2014/85138293747.cfm

Best,

bw

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up